DCM
TVRD

DAFNA Capital Management’s Tvardi Therapeutics TVRD Stock Holding History

DAFNA Capital Management’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-8,750
Closed -$4.5M – 88
2021
Q2 		$4.5M Buy
8,750
+1,488
+20% +$943K 0.94% 28
2021
Q1 		$5.68M Hold
7,262
– – 1.35% 21
2020
Q4 		$3.96M Buy
7,262
+390
+6% +$204K 1.18% 21
2020
Q3 		$3.15M Sell
6,872
-3,434
-33% -$1.99M 1.02% 25
2020
Q2 		$6.34M Hold
10,306
– – 1.83% 17
2020
Q1 		$4.9M Buy
10,306
+1,180
+13% +$641K 2.05% 13
2019
Q4 		$5.29M Sell
9,126
-1,400
-13% -$982K 1.82% 14
2019
Q3 		$6.93M Buy
10,526
+4,831
+85% +$4.02M 2.61% 8
2019
Q2 		$4.41M Buy
5,695
+1,706
+43% +$1.2M 1.66% 18
2019
Q1 		$2.82M Hold
3,989
– – 1.22% 28
2018
Q4 		$1.87M Buy
3,989
+855
+27% +$552K 0.93% 32
2018
Q3 		$2.7M Buy
3,134
+1,389
+80% +$1M 1.11% 32
2018
Q2 		$1.2M Sell
1,745
-861
-33% -$438K 0.56% 46
2018
Q1 		$1.16M Hold
2,606
– – 0.56% 50
2017
Q4 		$1.15M Hold
2,606
– – 0.62% 47
2017
Q3 		$1.28M Buy
+2,606
New +$1.31M 0.8% 39
2017
Q2 		– Sell
-2,648
Closed -$1.75M – 80
2017
Q1 		$1.75M Sell
2,648
-3,172
-55% -$1.69M 1.48% 24
2016
Q4 		$1.95M Sell
5,820
-1,598
-22% -$513K 1.71% 23
2016
Q3 		$2.23M Hold
7,418
– – 1.55% 23
2016
Q2 		$1.28M Hold
7,418
– – 1.02% 33
2016
Q1 		$1.66M Buy
7,418
+2,714
+58% +$811K 1.43% 21
2015
Q4 		$2.85M Buy
4,704
+2,105
+81% +$1.16M 2.55% 11
2015
Q3 		$1.34M Sell
2,599
-928
-26% -$621K 1.33% 23
2015
Q2 		$1.54M Buy
+3,527
New +$1.36M 1.31% 28

Other funds holding TVRD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $5.91B AUM 53.97% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.17B AUM 42.44% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

DAFNA Capital Management's TVRD Position: Q3 2021 in Review

DAFNA Capital Management sold out of Tvardi Therapeutics (TVRD) in Q3 2021, closing a stake of 8,750 shares — an estimated $4.5M sold.

DAFNA Capital Management first reported a position in TVRD in Q2 2015 and held it in 24 quarters. The position peaked at $6.93M in Q3 2019. 170 funds tracked by Wall St. Rank hold TVRD as of Q3 2021.

  • DAFNA Capital Management reported no remaining Tvardi Therapeutics position as of Q3 2021 after selling out during the quarter.
  • DAFNA Capital Management sold 8,750 Tvardi Therapeutics shares in Q3 2021, an estimated $4.5M.
  • DAFNA Capital Management first reported a position in Tvardi Therapeutics in Q2 2015 and held it in 24 quarters.
  • DAFNA Capital Management's Tvardi Therapeutics position peaked at $6.93M in Q3 2019.
  • 170 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q3 2021.

Based on DAFNA Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.